Alltracel's third-quarter revenue up 10%, new joint venture launched

By Lisa Kerner

Charlotte, N.C., Oct. 11 - Alltracel Pharmaceuticals plc said its third-quarter revenue was up 10%, at €5.5 million, over the same quarter of last year. Year-to-date revenue for 2006 is up 12%, at €15.0 million, from the same period in 2005.

"As well as reorders from current customers, particularly in oral care, as expected this quarter saw the start of Asia wound care shipments following regulatory clearances secured in China and Japan," chief executive officer Tony Richardson said in a company news release.

"We remain confident in the outlook for the final quarter and are comfortable with analysts' expectations of the business reaching full year profitability by year end."

The company also announced the launch of Nanopeutics Sro, a joint venture with Prague, Czech Republic-based Elmarco, to commercialize Elmarco's patented Nanospider-based technology solutions.

Alltracel is a medical technology company based in Dublin, Ireland.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.